REFERENCES
1. Crossley KB and Peterson PK. Infections in the Elderly. In: Bennett
JE, Dolin R, Blaser MJ (Eds). Mandell, Douglas, and Bennett’s Principles
and Practice of Infectious Diseases. 8th edition. Philadelphia, Elsevier
Saunders; 2015, pp 3459-3465.
2. Justo JA, Bosso JA. Advers reactions associated with systemic
polymyxin therapy. Pharmacotherapy 2015; 35(1): 28-33.
3. Hassan MM, Gaifer Z, Al-Zakwani IS. Incidence and risk factors of
nephrotoxicity in patients on colistimethate sodium. Int J Clin Pharm
2018; 40(2): 444-449.
4. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM.
Colistin: an update on the antibiotic of the 21stcentury. Expert Rev Anti Infect Ther 2012; 10(8): 917-934.
5. Aydoğan BB, Yıldırım F, Zerman A, Gönderen K, Türkoğlu M, Aygencel G.
Colistin nephrotoxicity in the ICU: Is it different in the geriatric
patients? Aging Clin Exp Res 2018; 30: 573-580.
6. Balkan II, Doğan M, Durdu B, et al. Colistin nephrotoxicity inreases
with age. Scand J Infect Dis 2014; 46: 678-685.
7. Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S.
Attributable Risk and Time Course of Colistin-Associated Acute Kidney
Injury. Clin J Am Soc Nephrol 2018; 13(4): 542-550.
8. Kwon KH, Oh JY, Yoon YS, et al. Colistin treatment in
carbapenem-resistant Acinetobacter baumannii pneumonia patients:
Incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents 2015;
45(6): 605-609.
9. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk
factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents
2009; 34(5): 434-438.
10. Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE
criteria. J Intensive Care Med 2007; 22(4): 187-193.
11. Horan T, Andrus M, Dudeck M. CDC/NHSN surveillance definition of
health care associated infection and criteria for specific types of
infections in the acute care setting. Am J Infect Control 2008; 36:
309–332.
12. Avedissian SN, Liu J, Rhodes NJ, et al. A Review of the Clinical
Pharmacokinetics of Polymyxin B. Antibiotics (Basel). 2019 Mar
22;8(1):31.
13. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk
factors for acute kidney injury in patients treated with polymyxin B or
colistin methanesulfonate sodium. Int J Antimicrob Agents 2014; 43(4):
349-352.
14. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy
LM, Apisarnthanarak A. Colistin-based treatment for extensively
drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob
Agents 2014; 43(4): 378-382.
15. Al-Abdulkarim DA, Alzuwayed OA, Al Ammari M, Al Halwan S, Al Maklafi
N, Thomas A. Colistin-induced Nephrotoxicity in a Tertiary Teaching
Hospital. Saudi J Kidney Dis Transpl. 2020 Sep-Oct;31(5):1057-1061.
16. Gunay E, Kaya S, Baysal B, Yuksel E, Arac E. Evaluation of prognosis
and nephrotoxicity in patients treated with colistin in intensive care
unit. Ren Fail. 2020 Nov;42(1):704-709.
17. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with
intravenous colistin in critically ill patients. Pharmacotherapy. 2011
Dec;31(12):1257-64.
18. Busca C, Moga DC, Farcas A, Mogosan C, Dumitrascu DL. An
investigation of the concomitant use of anjiotensin-converting enzyme
inhibitors, non-steroidal anti-inflammatory drugs and diuretics. Eur Rev
Med Pharmacol Sci 2015; 19(15): 2938-44.
19. Özkarakaş H, Köse I, Zincircioğlu Ç, et al. Risk factors for
colistin-associated nephrotoxicity and mortality in critically ill
patients. Turk J Med Sci 2017 Aug 23;47(4): 1165-1172.
20. Koksal I, Kaya S, Gencalioglu E, Yilmaz G. Evaluation of risk
factors for intravenous colistin use-related nephrotoxicity. Oman Med J
2016 Jul; 31(4): 318-21.
21. Ageing and health. Available from:https://www.who.int/news-room/fact-sheets/detail/ageing-and-healthAccessed: 10 April 2019.
22. Kline KA, Bowdish DM. Infection in an aging population. Curr Opin
Microbiol. 2016 Feb; 29:63-67.
23. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the
elderly. Chest. 2003 Jul;124(1):328-336.
24. Liang SY. Sepsis and Other Infectious Disease Emergencies in the
Elderly. Emerg Med Clin North Am. 2016 Aug;34(3):501-522.
25. Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic
pharmacokinetic principles in the critically ill. Intensive Care Med.
2013 Dec;39(12):2070-82.
26. Bradley SF. Principles of Antimicrobial Therapy in Older Adults.
Clin Geriatr Med. 2016 Aug;32(3):443-57.
27. Pagani L. Appropriate antimicrobial therapy in the elderly: when
half-size does not fit all frail patients. Clin Microbiol Infect. 2015
Jan;21(1):1-2.
28. Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a
lifesaver for the 21st century? Expert Opin Drug Metab Toxicol. 2017
Jan;13(1):59-71.
29. Grégoire N, Aranzana-Climent V, Magréault S, Marchand S, Couet W.
Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin
Pharmacokinet. 2017 Dec;56(12):1441-1460.
30. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin
nephrotoxicity. Eur J Clin Pharmacol. 2015 Jul;71(7):801-10.